Efavirenz Metabolism and CNS Toxicity in Ugandan Children: CYP2B6 Genotype Impact

99 Ugandan children aged 3–12 years were prospectively followed from 2015–2016 to study the antiretroviral drug efavirenz. Plasma samples at 2, 6, 12, and 24 weeks post-treatment were analyzed for EFV and its metabolites using liquid chromatography high-resolution tandem mass spectrometry. The study, authored by Sandra Soeria-Atmadja, links metabolite ratios and CNS symptoms to CYP2B6 metabolizer phenotypes.

Use Cases

• Modeling the relationship between CYP2B6 genotype and efavirenz metabolite ratios based on plasma measurements.
• Investigating associations between high efavirenz plasma concentrations (>4,000 ng/mL) and mild CNS adverse effects.
• Studying autoinduction of drug metabolism in CYP2B6 extensive metabolizers over a 24-week period.
• Analyzing the distribution patterns of conjugated vs. unconjugated drug metabolites across different metabolizer phenotypes.

Strengths

• Includes longitudinal data with plasma sampling at four time points over 24 weeks.
• Quantifies multiple efavirenz metabolites (8-OH-EFV, 7-OH-EFV, EFAdeg) in both conjugated and unconjugated forms.
• Links clinical CNS symptom assessments to genetic CYP2B6 metabolizer phenotypes and precise plasma drug concentrations.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (25.7 KB), indicating limited scope, likely a supplementary document.

Provenance

Source

figshare, author Sandra Soeria-Atmadja.

Collection Method

Prospective clinical study with plasma sampling, genotyping, and LC-HRMS/MS analysis.

Time Range

Data collection occurred in 2015–2016.

Freshness

Last updated 2026-04-24 05:40:36; freshness should be verified.

Geography

Study conducted with a cohort of Ugandan children.